To include your compound in the COVID-19 Resource Center, submit it here.

Wait begins for Protara data

Gensia Inc. on Friday announced that it has completed enrollment of its third Phase III trial of Protara (acadesine) in patients undergoing coronary artery bypass graft surgery. The decision was in accordance with the trial's clinical protocol based on group sequential analysis.

Tea leaf readers will have 10 weeks to sift for meanings, while GNSA collects and analyzes the data on its adenosine regulating agent. If the results are favorable, the San Diego company will submit the data in the fourth

Read the full 818 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE